Patents by Inventor Gordan Dougan

Gordan Dougan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Vaccines containing bacteria attenuated by mutation of the htrA gene
    Patent number: 5980907
    Abstract: Attenuated microorganism for use in immunoprophylaxis in which the attenuation is brought about by the presence of a mutation in the DNA sequence of the microorganism which encodes, or which regulates the expression of DNA encoding a protein that is produced in response to environmental stress, the microorganism optionally being capable of expressing DNA encoding a heterologous antigen.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 9, 1999
    Assignee: Glaxo Wellcome Inc.
    Inventors: Gordan Dougan, Ian George Charles, Carlos Estenio Hormaeche, Kevin Stuart Johnson, Steven Neville Chatfield
  • Live vaccines
    Patent number: 5851519
    Abstract: The present invention discloses a novel approach to attenuating bacteria and for their use as live vaccines. The vaccines can be used in human and animal medicine.In particular, there is disclosed a method of attenuating a bacteria by mutating a gene concerned with the regulation of one or more genes concerned with expression of outer membrane proteins, particularly porin proteins.
    Type: Grant
    Filed: April 10, 1995
    Date of Patent: December 22, 1998
    Assignees: Glaxo Wellcome Inc., The Royal Society, The Lister Institute of Preventive Medicine, The University Court of The University of Dundee
    Inventors: Gordan Dougan, Steven Neville Chatfield, Christopher Francis Higgins, Charles James Dorman
  • Vaccines containing a salmonella bacteria attenuated by mutation of the htra gene
    Patent number: 5804194
    Abstract: Attenuated microorganism for use in immunoprophylaxis in which the attenuation is brought about by the presence of a mutation in the DNA sequence of the microorganism which encodes, or which regulates the expression of DNA encoding a protein that is produced in response to environmental stress, the microorganism optionally being capable of expressing DNA encoding a heterologous antigen.
    Type: Grant
    Filed: December 7, 1994
    Date of Patent: September 8, 1998
    Assignee: Glaxo Wellcome Inc.
    Inventors: Gordan Dougan, Ian George Charles, Carlos Estenio Hormaeche, Kevin Stuart Johnson, Steven Neville Chatfield
  • Vaccines comprising attenuated salmonella having mutations in the ompr genes
    Patent number: 5527529
    Abstract: The present invention discloses a novel approach to attenuating bacteria and for their use as live vaccines. The vaccines can be used in human and animal medicine.In particular, there is disclosed a method of attenuating a bacteria by mutating a gene concerned with the regulation of one or more genes concerned with expression of outer membrane proteins, particularly porin proteins.
    Type: Grant
    Filed: April 10, 1995
    Date of Patent: June 18, 1996
    Assignees: The Wellcome Foundation Limited, The Royal Society, The Lister Institute of Preventive Medicine, The University Court of The University of Dundee
    Inventors: Gordan Dougan, Steven N. Chatfield, Christopher F. Higgins, Charles J. Dorman